BIONTECH SE (BNTX): Price and Financial Metrics


Today's Latest Price: $50.13 USD

1.03 (-2.01%)

Updated Jun 4 2:20pm

Add BNTX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

BNTX Daily Price Range
BNTX 52-Week Price Range

BNTX Stock Price Chart More Charts

BNTX Price/Volume Stats

Current price $50.13 52-week high $105.00
Prev. close $51.16 52-week low $12.52
Day low $49.70 Volume 467,311
Day high $51.86 Avg. volume 896,754
50-day MA $49.20 Dividend yield N/A
200-day MA $0.00 Market Cap 11.34B


BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.

BNTX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

BNTX Latest Social Stream

Loading social stream, please wait...

View Full BNTX Social Stream

Latest BNTX News From Around the Web

Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.

NYT: Trump identifies five drugmakers most likely to produce a viable COVID-19 vaccine

The Trump administration has reportedly named five drugmakers that it expects to be the most likely to produce a viable COVID-19 vaccine, according to The New York Times, which cited people familiar with the matter. This includes AstraZeneca in combination with Oxford University, Johnson & Johnson , Moderna Inc. , Merck & Co. Inc. , and Pfizer in combination with BioNTech SE . With the exception of Merck, Pfizer, and BioNTech, shares of those companies were up in afternoon trading on Wednesday. Inovio Pharmaceuticals Inc. , an early vaccine contender, was not included in the Times' report. Its stock was down 10.8%. Much of the nation's hopes for an economic recovery are tied to the development of a vaccine that can successfully prevent people from becoming infected with COVID-19. The a...

Yahoo | June 3, 2020

How BioNTech (BNTX) Stock Stands Out in a Strong Industry

BioNTech (BNTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research | June 1, 2020

Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners

Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.

Yahoo | June 1, 2020

Here's the Under-the-Radar Biotech That Could Beat Moderna at Its Own Game

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), who has himself been in the limelight in recent months, even singled out the biotech days ago for what he called its "quite promising" COVID-19 vaccine candidate. Moderna has deservedly received a lot of attention from the press and from investors. This under-the-radar biotech just might even beat Moderna at its own game.

Yahoo | May 31, 2020

Another coronavirus vaccine candidate might be ready sooner than expected

Another potential coronavirus vaccine might be available this fall. Pfizer said the candidate it’s developing with BioNTech could be ready by October if everything goes well. There’s no guarantee that any of these vaccines will work, and several logistic challenges have to be addressed before mass immunization campaigns can be conducted. The development of vaccines for the novel coronavirus has been rather promising so far, with more than 100 teams moving forward with drugs for neutralizing the virus and preventing infection. Separately, research has shown that COVID-19 survivors will be immune, and that vaccine candidates can induce the same kind of immunity in subjects. While it’s still unclear how long COVID-19 protection lasts , vaccines would make the disease a lot easier to contro...

BGR | May 30, 2020

Read More 'BNTX' Stories Here

BNTX Price Returns

1-mo 0.26%
3-mo 31.61%
6-mo 105.70%
1-year N/A
3-year N/A
5-year N/A
YTD 47.96%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0779 seconds.